跳至主要内容
临床试验/NCT01955967
NCT01955967已完成不适用

The Effect of Intravenous Lidocaine on Trigeminal Neuralgia

Pain Relief & Palliative Care Center, Athens, Greece0 个研究点目标入组 20 人开始时间: 2006年4月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
20
主要终点
Pain intensity

研究概览

简要总结

The aim of this randomized double blind, placebo controlled, crossover study is to investigate in a prospective way the effect of lidocaine in patients with trigeminal neuralgia. Included patients will undergo four weekly sessions, two of which with lidocaine (5mgs/kg) and two with placebo infusions administered over 60 minutes. Effect will be measured with pain diaries and visual analogue scales.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Supportive Care
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • (1) confirmed diagnosis of TN according to IASP definition, (2) age equal to or greater than 18 years, (3) visual analogue scale (VAS) score equal to or greater than 3 (out of a maximum 10), (4) DN4 score equal to or greater than 4 (out of a maximum 10), (5) having received the recommended medications for TN (antiepileptics, spasmolytics, opioids, anti-inflammatory and simple analgesic drugs) for an adequate period without therapeutic results, (6) TN duration of at least 12 months, (8) no history of allergy to lidocaine, (9) no history of substance abuse, (10) absence of severe psychiatric diseases, (11) not being pregnant, (12) not lactating, (13) absence of severe cardiac, hepatic and renal decease, and (14) be willing to provide a written informed consent to undergo the experimental procedures.

排除标准

  • 未提供

研究组 & 干预措施

Lidocaine

Other

干预措施: Lidocaine (Drug)

结局指标

主要结局

Pain intensity

时间窗: 24h

次要结局

未报告次要终点

研究者

发起方
Pain Relief & Palliative Care Center, Athens, Greece
申办方类型
Other
责任方
Sponsor

相似试验